Form 424B5 Intra-Cellular Therapies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intra-Cellular Therapies (ITCI) PT Raised to $96 at Mizuho
April 22, 2024 5:34 AM EDTMizuho analyst Graig Suvannavejh raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $96.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "On the heels of the first Phase 3 data in major depressive disorder/MDD for ITCI's lead asset lumateperone/Caplyta... More
